Incannex Starts Phase 3 OSA Trial; Nasdaq Cure Still Needed

What happened

Incannex Healthcare announced the official commencement of the DReAMzz clinical study for IHL-42X in obstructive sleep apnea, with all clinical sites identified and trial infrastructure activated. This marks a key operational milestone that transitions the lead program from planning to execution, addressing one of the core catalysts identified in the DeepValue master report. However, the company's Nasdaq minimum bid price compliance deadline of April 20 has passed without a disclosed cure, keeping listing risk active. The stock remains highly dilutive given prior ATM issuance and substantial additional funding needs. While the Phase 3 initiation is positive, the full re-rating requires confirmation of both trial enrollment and a sustainable Nasdaq listing solution.

Implication

In the near term, the Phase 3 start should support sentiment and may lift the stock toward the $0.32 base case, but the missing Nasdaq cure caps upside. Long-term, if the company secures both a Nasdaq cure and steady enrollment, the bull case of $0.50 becomes more probable. However, failure to resolve listing issues could lead to the bear case of $0.16. Investors should wait for an 8-K or proxy regarding the bid price compliance before adding significant exposure.

Thesis delta

Previously, the investment thesis hinged on awaiting Phase 3 initiation and Nasdaq cure. With the Phase 3 now recruiting, the odds of the bull case have measurably increased. However, the failure to disclose a Nasdaq cure by the April 20 deadline introduces a new binary risk that tempers the positive news. The thesis shifts from 'wait for both catalysts' to 'partial confidence in Phase 3 execution, but listing uncertainty remains dominant.'